Operator
Good morning, ladies and gentlemen, and thank you for standing by for Waterdrop Inc.' s Second Quarter 2026 Financial Results Earnings Conference Call.
At this time, all participants are in a listen-only mode. After the management's prepared remarks, there will be a question-and-answer session.
As a reminder, today's conference call is being recorded. I would now like to turn the meeting over to Ms.
Tracy Lee. Please proceed, Ms.
Li.
Tracy Lee
Thank you, operator. Dear investors and analysts, this is Tracy Lee from Waterdrop Investor Relations.
Please note that discussion today will contain forward-looking statements made under the safe harbor provisions of U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from our current expectations. Potential risks and uncertainties include, but not limited to, those outlined in our public filings with the SEC.
The company does not undertake any obligation to update any forward-looking statement, except as required under applicable law. Also, this call includes discussion of certain non-GAAP measures.
Please refer to our earnings release for reconciliation between non-GAAP and GAAP. Joining us today on the call are Mr.
Shen Peng, our founder, chairman, and CEO; Mr. Ran Wei, director and GM of insurance business; Mrs.
Li Jieru, Finance VP, head of strategy and capital markets. Certain members of our management team will deliver their remarks in Mandarin, followed by an English translation.
Moreover, a webcast replay will be available on our investor relations website. I will now turn the call over to our CEO, Shen Peng.
Please go ahead.
Peng Shen
尊敬的各位投资者、分析师朋友,大家好!感谢各位参加水滴公司2026年第二季度业绩电话会。二季度,公司业务保持增长态势,整体收入约14.5亿元,同比增长72.8%,归母净利润约1.3亿元。自2022年一季度来,公司连续18个季度保持GAAP口径盈利。分业务来看,保险业务持续优化获客渠道与转化效率,季度收入同比增长80.5%。水滴筹稳健经营,截至季度末,已累计为382万名大病患者筹集了医疗资金。数智临床试验解决方案业务高效交付,单季度入组患者同比提升超过50%。支撑这些业务增长,是AI能力在核心业务场景的深度落地。这也在不断巩固公司的竞争壁垒。截至6月底,公司已申请大模型相关专利88项,含境外专利10项。基于持续稳健的盈利能力和充足的现金储备,公司持续重视股东回报。我们很高兴地宣布,近期公司董事会已经批准以下两项决议:一方面,公司将于近期启动第六次现金派息,计划于11月上旬,向截至美东时间2026年10月9日收盘时,持有普通股和ADS的股东派发股息,每ADS派息0.03美元,每普通股派息0.003美元,派息总额约1080万美元。另一方面,董事会已批准第六期回购计划,授权公司在未来一年内,以总额5000万美元为上限,继续在公开市场回购股份。自2021年宣布首期回购计划以来,截至2026年8月末,公司已累计回购约6290万股ADS,耗资约1.21亿美元。公司始终秉持可持续发展理念,切实回馈社会。截至2026年6月30日,水滴公益平台已与119家公募慈善组织开展合作,上线超1.56万个公益项目。借力持续聚焦主业的增长和投入,我们预期当期增长投入将持续转化为坚实的业务基础与未来的利润空间。我们相信科技是公司的发展核心引擎,当前AI能力已深度嵌入各个业务平台,使我们能够更精准地把握住既有业务中不断增长的市场需求,巩固并增强竞争壁垒。与此同时,我们也在积极地孵化面向全球的AI驱动的新业务,并在局部市场已经取得了初步进展。面向2026年全年,我们预期收入同比增长40%以上,营业利润同比增长10%以上。以上是水滴公司的整体业绩表现,接下来我们将展开介绍各业务的情况。
Tracy Lee
Dear investors and analysts, thank you for joining Waterdrop second quarter 2026 earnings conference call. In this quarter, we maintain growth momentum and achieve a total revenue of 1.45 billion yuan, up 72.8% year-over-year, and a net profit attributable to our ordinary shareholders of 130 million yuan.
Since the first quarter of 2022, we have maintained profitability for 18 consecutive quarters. Segment-wise, our insurance business continued to optimize user acquisition and conversion, driving 80.5% year-over-year revenue growth.
Waterdrop Medical Crowdfunding have cumulatively raised medical funds for 3.82 million patients as of the quarter-end. Our digital clinical trial solution business performed strongly, with quarterly patient enrollment up over 50% year-over-year.
These growth trends were underpinned by deep integration of AI across our core business scenarios. As at the end of June, the company has filed 88 large-language-model patents, including 10 of them overseas.
With strong performance and cash reserves, we continue to prioritize shareholder returns. Our board recently approved two new initiatives.
Firstly, the board has approved a cash dividend of $0.03 per ADS or $0.003 per ordinary share, payable to holders of the record on October 9, 2026. The aggregate dividend payment is approximately $10.8 million, with payment to be made in early November.
Second, the board approved the sixth share repurchase program of up to $50 million over the next 12 month. Since the initial program launched in 2021, we have repurchased approximately 62.9 million ADS for $121 million as of August 31st, 2026.
The company remains committed to sustainable development and to giving back to society in meaningful ways. As of June 30, 2026, Waterdrop charity platform has partner with 119 public charitable organizations and launched more than 15,600 charity programs.
Waterdrop remains focused on growth and investment in core businesses. We expect that our current incremental investment to continue to translating into solid user base and huge future productivity potential.
We always regard technology as the core driver of the company's growth. Today, our AI capabilities actively blended across the platforms, enabling us to better capture growth opportunities in our existing businesses and further sharpen our competitive edge.
At the same time, we are actively piloting new AI-driven initiatives for global markets and have made early progress in select markets. For full year of 2026, Waterdrop targets more than 40% year-over-year growth in total revenue and over 10% growth in operating profit.
This conclude our overview of Waterdrop's business performance. Now, we will walk you through each of our business segments in more detail.
Ran Wei
大家好,我是冉伟,我来汇报一下保险业务的进展。二季度保险业务相关收入达13.3亿元,同比增长80.5%,环比提升16.4%,业务经营利润约1.8亿元,环比提升20%。基于AI模型在用户需求洞察与转化上的持续打磨,转化效率环比优化,季度内新用户环比增长32.3%。供给方面,凭借需求洞察和多元供给能力,我们及时承接住了本季度分红储蓄型产品的需求窗口,带动长险保费环比增长33.4%。
Tracy Lee
Hello everyone, this is Ran Wei. Let me briefly update you on our insurance business.
In the second quarter, insurance-related income reached 1.33 billion yuan, up 80.5% year-over-year and 16.4% quarter-over-quarter. Operating profit was 180 million yuan, up 20% from the previous quarter.
With continued refinement in our AI-driven user insights and conversion capabilities, newly acquired customers rose 32.3% sequentially. The first-year premium of long-term insurance grew 33.4% sequentially as we captured market demand for endowment insurance this quarter.
Ran Wei
在供给端,提升保险产品的可及性是我们在产品端持续发力的主体策略。本季度在这个方向又有两款产品落地。重疾险方向,我们推出了业内首款免告知、5年保证续保的长期重疾险产品容易保,涵盖超百种重大疾病,并可附加意外身故与伤残保障。同时拓宽针对高照需求的矩阵,新增业内首款终身免告知的特定疾病保险。二季度,我们的带病体系列产品贡献保费约3.1亿元,失能险贡献保费约8400万元。
Tracy Lee
On the product side, our core strategy remains improving the accessibility of insurance products. This quarter, we delivered several new products in line with this direction, including the launch of Rongyibao, the market-first long-term critical illness insurance product requiring no health disclosure and offering five-year guaranteed renewability.
We also expanded our [dixing gaozhao?] product matrix, which now includes the market-first specific disease insurance offering lifetime coverage with no health disclosure.
During this quarter, products for users with pre-existing conditions contributed 310 million yuan in FYP, and disability insurance added 84 million.
Ran Wei
在服务端,我们针对不同触达方式做了差异化的场景运营。本季度,C端交互场景AI应用整体辅助实现保费近1亿元。其中,小程序首页的AI专业宝有效承接自然流量,月度带动百万级保费承单。在交互深度更高的语音场景中,AI医疗险专家转化效果更为突出,单季度辅助实现保费环比增长25.6%。企信服务场景中,从需求挖掘、画像定位到关键节点触达和批量推送,AI可以直接承载策略的执行,将运营意图穿透到位,季度辅助实现总保费超1000万元。
Tracy Lee
On the service side, we've adopted differentiated scenario-based operations across customer touch points. In this quarter, AI applications across our user-facing interactions scenarios helped generating nearly 100 million yuan in FYP.
Among them, AI Pro Insurance generates FYP in millions each month. FYP facilitated by our AI medical insurance experts grew by 25.6% sequentially.
In WeChat scenario, AI executed our strategies directly, from the demand identification and user profiling to key moment engagement and batch outreach, contributing over 10 million yuan in FYP during this quarter.
Ran Wei
在长险销售方向,AI的价值最终落在顾问产能的释放上。截至季度末,核保助手可疑点AI累计回答核保问题已突破1.3万次。在超级售前小助理自上线后单线条产能持续领先人工,季度内承接用户环比提升至近50%。多智能体协同下的AI转化模型能够从自然语言交互中捕捉用户偏好,提炼为可跨周期调用的特征,并主动触发匹配的热点议题,有效延伸顾问的服务半径。以上就是二季度保险科技业务相关的情况。
Tracy Lee
In long-term insurance sales, the value of AI ultimately comes down to expanding what our life planners can do. As of quarter-end, our underwriting assistant, [keyi.ai?]
, had answered more than 13,000 underwriting questions. Since its launch, our AI super pre-sales assistant has constantly outperformed human life planners on annual premium per lead, and the number of users is served grew nearly 50% sequentially.
Powered by multi-agent collaboration, our AI conversion model captures user preference from natural language interactions, turning them to durable profile we can draw on over time, and proactively surface topics tailored to each users, effectively extending the reach of every life planner we have. That concludes our update on the insurance business for the second quarter.
Ran Wei
接下来我来汇报一下筹和医行业务在二季度的表现。截至2026年6月底,水滴筹捐款人数累计约4.99亿人,累计救助患者达到382万人,累计筹款金额约747亿元。本季度,我们继续聚焦AI风控模型,重点推进两个关键模块的迭代进展:一是资产隐瞒识别模块。原有方式中,风控策略更多依赖基于业务经验人工设定的规则。本季度,我们进一步扩大AI语言理解能力的深度应用,以模型协同的方式对申诉、佐证、医疗材料与用户生产内容进行联合语义分析,识别房产、车产以及收入等维度的隐瞒信息,利用AI风控模型对信息的真实性与关联性做出研判,自动识别其中可能存在的资产状况隐性矛盾。升级后的风控模型相较原有正规规则覆盖更全面,抓取更精准,审核效率显著提升。二是敏感身份识别模块。水滴筹通过社交媒体信息、文案素材、行路作证等要素进行联合语义分析,系统可识别有高话题性身份的群体,并据此及时开展舆情风险评估与升级。基于AI模型对职业与收入的区间推断,该模块目前无需依赖人工维护的先验规则,即可完成对案例发起人身份的自主识别,并有效地将潜在风险拦截在发酵之前。
Tracy Lee
Next, let me briefly update on Waterdrop medical crowdfunding and healthcare businesses. As of the end of June 2026, Waterdrop medical crowdfunding had cumulatively contribution from around 499 million donors, helped 3.82 million patients, and raised a total of 74.7 billion yuan.
This quarter, we continue to upgrade our AI-driven risk control models, further improving asset concealment detection and sensitive identity detection. By combining semantic analysis of ID information, medical materials, and user-generated content, the upgraded engine can better identify hidden inconsistency and improve risk control efficiency.
Ran Wei
二季度,医药业务经营表现全面超预期。单季度入组患者超1500名,同比增长54%,累计服务患者突破1.7万人。本季度核心增长的驱动力是匹配效率交付能力的提升。基于材料结构化能力与AI匹配模型的迭代,平台能够处理更复杂的入排标准,覆盖更多低发病种特征,季度内进一步释放产能。病种结构方面,肿瘤方向为水滴履约基本盘,继续贡献核心体量;慢病方向则驱动本季度主要增量。慢病方向虽患者基数大,但项目普遍筛败率高,对于招募平台的匹配精度和速度要求高。二季度,慢病入组患者同比提升80%,有力证明了平台在高效筛败率场景的稳定交付能力。与此同时,履约口碑的积聚正向转化为更深更广的合作信任。二季度,翼帆医药新签项目达167个,合作药企及CRO突破255家。未来,我们会全面做好经营效率优化,致力于与合作伙伴共同提升临床试验环节的数字化水平。以上是筹和医药业务的相关情况。
Tracy Lee
In our healthcare businesses, our performance exceeding expectation across several key metrics. We enrolled more than 1,500 patients in this quarter, up 54% year-over-year, and cumulative patient served surpassing 17,000.
Growth were driven mainly by the higher matching efficiency and a stronger enrollment capability. Oncology projects remained our core focus, while chronic disease projects have driven most of the sequential growth this quarter.
Although chronic disease studies have a larger patient pool, they typically carry a high screening failure rates, and place greater demand on matching precision and speed. Chronic disease enrollment increased 80% year-over-year in the second quarter, further validating our enrollment ability in high screening failure scenario.
Meanwhile, our proven enrollment track record is translating into deeper and broader trust among partners. In this quarter, E-帆 platform signed 167 new projects, and the number of pharmaceutical companies and CROs we partnered with surpassed 255.
Moving forward, we will continue to optimize operational efficiency and work with our partners to advance digitalization across the clinical disease profession. This concludes our update on the crowdfunding and healthcare businesses.
Jieru Li
Hello everyone, this is Li Jieru. Next, I will walk you through our financial highlights for the second quarter of 2026.
Before I go into details, please be reminded that all the numbers quoted here will be in RMB, and please refer to our earnings release for detailed information on financial performance on both the year-over-year and quarter-over-quarter basis, respectively. In the second quarter of 2026, Waterdrop delivered net operating revenue of 1,448 million yuan, up 72.8% year-over-year, maintaining a strong growth momentum.
Our insurance business contributed about 1,333 million yuan in revenue, representing an 80.5% increase year-over-year. Non-insurance businesses accounted for around 7.9% of total revenue, including 63.6 million yuan from medical crowdfunding service fees and 35.2 million yuan from our digital clinical trial solutions.
Total operating costs and expenses came in at about 1,337 million yuan in the second quarter, up 80.5% year-over-year. Operating costs were 537 million yuan, increasing 29% year-over-year.
The increase was primarily driven by business scale expansion, including an increase of around 63.8 million yuan in cost of referrals and service fees, as well as an increase of 21.4 million yuan in short message service costs and 11.2 million yuan in personnel costs, respectively. Sales and marketing expenses reached nearly 638 million yuan, compared with 199 million yuan in the same quarter of 2025.
The year-over-year increase mainly reflect- the year-over-year increase mainly reflected our active step-up in public domain traffic investment, with marketing expenses for third-party traffic channels increasing by about 415 million yuan, and marketing-related professional technical service fees increasing by around 21.8 million yuan. G&A expenses were 93.4 million yuan, up 27.2% year-over-year, mainly due to an increase of 33.3 million yuan in allowance for credit losses.
This was partially offset by decreases of nearly 10.5 million yuan in personnel costs and share-based compensation expenses. R&D expenses were 68.8 million yuan, up 32.4% year-over-year.
The increase was mainly driven by cloud server fees, token fees, and other IT support expenses, which rose by about 11.1 million yuan, as well as an increase of 6.3 million yuan in personnel costs and share-based compensation expenses. For this quarter, operating profit reached about 111 million yuan, up 14.3% year-over-year and 39.2% quarter-over-quarter.
However, due to tax-related items and nonrecurring gains and losses, net profit attributable to shareholders was around 126 million yuan, down 10.3% year-over-year, but up 27.9% quarter-over-quarter. As of June 30, 2026, cash and cash equivalents, short-term investments, and other cash positions totaled about 2.653 billion yuan.
Our cash reserve maintains ample and provide solid support for both business investments and shareholder returns. In terms of shareholder returns, since the launch of our first share repurchase programs, we have cumulatively repurchased 62.9 million ADS for a cost of approximately 120 million U.S.
dollars as of August the 31st, 2026. Recently, the board approved the sixth share repurchase program, under which we plan to repurchase up to $50 million over the next 12 months, and also approved the sixth cash dividend of approximately 10.8 million U.S.
dollars. Overall, both the quality and scale of growth in our core businesses improved this quarter.
The continued deployment of AI across every scenario in our business is becoming an important driver of efficiency gains. Meanwhile, we're expanding proactively while investing prudently in new initiatives in global markets, which for now have very limited impact on our current period financial results.
As these initiatives reach a larger scale, we will keep the capital markets informed in a timely manner. In the future, the company will remain committed to disciplined strategic investment and continue creating long-term value for users and shareholders.
That concludes the company's financial results for the second quarter of 2026. We will now move on to the Q&A session.
Tracy Lee
Thank you, Jieru. Ladies and gentlemen, we will now begin our Q&A session.
To ask a question, please press *1 on your telephone. To withdraw your question, please press *2.
In addition, this conference is being webcast live on the [Scene Enter?] platform.
If you're joining through the platform, you may also submit your question in writing there. We will now proceed to take our first question, and it comes from the line of Amy Chen of Citi.
The question is, in terms of mainland Chinese visitors business in Hong Kong, media have reported that mainland tax authorities may tax policy dividends. Has management seen any change either in international business or domestic business?
那么我们第一个问题来自于花旗分析师Amy Chen。她的问题是:近期关于港险内地访客保单收益征税的讨论比较多,想请教一下管理层如何解读对公司在内地保险以及国际化业务的影响?
Ran Wei
好,感谢Amy的提问,这个问题我来回答一下。关于近期市场关注的针对居民保险收益征税的信息,我们理解这是既有课税规则的落实,并非针对香港保险的新政。短期内,相关媒体报道确实对部分客户心态造成了一定影响。但香港保险产品在多币种配置、全球医疗、财富传承等方面的差异化价值是非常明确的。在满足对应客户群的相关需求上,仍然具备吸引力。保险市场的底层支撑逻辑是没有变化的。境内人身险市场的当前核心增长驱动力,来源于广大居民健康保障意识的持续增强,商业保险的多重政策利好,和产业链端持续的保险产品创新,以及当前低利率环境下居民储蓄向保险等长期稳健资产迁移的结构性趋势。而水滴公司覆盖多元客户群、多市场和多服务模式,整体业务组合非常稳健。无论客户需求落在哪个细分品类,我们都有信心和能力做好承接与服务。以上。
Tracy Lee
Regarding recent market attention, our reading is that what we are seeing reflects the enforcement of tax rules that has long been in place, rather than a new policy specifically targeting Hong Kong insurance. In the near term, the media coverage have some effect on our customers' sentiment.
The differentiated value of Hong Kong insurance products, like multi-currency allocation, access to global healthcare resources, and inheritance planning, are really clear, and fundamental drivers of the Hong Kong insurance market has not changed. Turning to the drivers of mainland China insurance market today, the growth is driven by rising health protection awareness, policy tailwinds for commercial health insurance, continued product innovation, and a structural shift of household savings into long-term assets such as insurance in the current low interest rate environment.
Waterdrop serves a diversified customer base across multiple markets and multiple service models, and our business mix remains solid, and we're confident in serving user demand wherever it lies. We will now take our next question from Xintao Chen of CCICC.
The question is, we have noticed that several insurers have recently launched health insurance products targeting customers with pre-existing conditions. How does management evaluate this opportunity in this category, and what is Waterdrop's product strategy in this area?
下个问题来自于中金公司分析师陈新涛。他的问题是:近期业内不少保司推出带病体相关保险,想请教一下管理层如何看待这一细分市场发展机遇,以及水滴是在如何规划这类产品的产品策略方面?
感谢涛总的提问。从大趋势上来讲,随着体检越来越普及,慢性病、带病生存人员越来越常见,统计学意义上的零瑕疵的完美标体其实已经很少。而传统健康险长期更擅长承保健康人,大量已病人群、慢病人群的保障需求是客观存在的。所以行业共识比较清楚,就是要从保更多健康人转向保更多人健康。这既是需求侧的机会,也是商保补充支付扩大覆盖面的确定性方向。带病体产品最典型的早期实践是各地的惠民保,现在已经逐步拓展到商业医疗险、重疾险、失能险等更多商保产品险种。这种延伸不是简单降低投保门槛,本质上是在细分疾病风险的基础上,建立差异化的承保与理赔模型,实现定向可保、可赔。降低投保门槛是水滴公司在产品定制策略上持续发力的主线。供给端,我们会按照多场景、多年龄层、多病种去识别需求重点,联合保司共同设计更优的承保条件准入范围。同时在获客端,借助互联网平台在AI应用端洞察方面的优势,让对的用户买到他适合的保险产品。中长期来看的话,随着未来医保和商保数据逐渐打通,保司和中介皆有能力把风控模型和服务能力做得更深。未来带病体健康险将有机会更接近车险这样的大众化保障,人人可投保、可理赔、可续保。我们也坚定地相信,带病体健康险在未来会更可及的同时,也做到更可持续。以上。
Tracy Lee
As checkups become more common, chronic illness and living with pre-existing conditions are far more typical. A clean, standard life is actually quite rare.
Traditional healthcare insurance have long focused on healthy lives, but millions of people with pre-existing conditions still go unprotected. The industry consensus is clear.
We're shifting from insuring more healthy people to protecting the health of more people. This is both a real demand side opportunity and a clear path of commercial insurance expanding its coverage.
Early practice was city-level inclusive health plans. That logic is now moving to more commercial medical insurance, critical illness insurance, disability insurance, and others.
This is not simply losing underwriting. It is segmenting the disease risk and building differentiated underwriting and claims, the certain risk can actually be written and paid.
For Waterdrop, lowering coverage threshold is central to our product strategy. At the supply side, we break demand down by scenarios, age, and conditions, and co-design terms and coverage with our insurer partners.
On the acquisition side, we use platform and AI insights to match the right product to the right customer, people with pre-existing conditions can actually find something that works for them. Longer term, our view is that health cover for people with pre-existing conditions can become more like auto insurance.
People can actually buy it, claim on it, and renew it. Accessibility and sustainability will have to move together.
We will now take our next two questions from Will Wu of Guotai Junan International. The questions is, is there a clear timeline for AI agents to start generating commercial value, and how will AI investment impact on R&D expenses ratio going forward?
What other new initiatives is the company currently exploring?
下面我们收到两个来自于国泰君安国际分析师吴柳的问题:请教一下管理层,AI Agent商业化价值产生是否有明确的时间线?AI投入对研发费用率有什么样的影响?以及目前公司还有哪些新方向、新生态领域的探索吗?
Peng Shen
感谢提问。关于我们这个AI的投入和商业化价值的衡量,包括公司在做的一些创新型的业务,我整体来回答一下。如前面业绩发布的时候我们也介绍过,我们公司的AI的能力其实是嵌入到核心业务,尤其是像保险业务的获客和保理赔等各个业务环节当中去的。所以我们看待AI商业化以及AI价值呢,也是基于各个环节的具体提效空间或者是增量空间的不同来去做衡量。那整体来说,我们还是希望能够通过AI能力和AI工具的全面融合,最终还是能够提升公司整体在财务上的收入增长的能力和利润创造的能力。所以我们认为AI Agent包括AI应用的价值呢,最后还是会体现到公司整体的业绩的交付上,我们不会有一个单独的AI板块的单独的商业化的区分。那也像前面说过,我们在不同的服务场景下,其实用AI的方式会不同。比如说我们在获客、C端转化的场景,那AI其实现在是可以直接参与用户关于保险的咨询和购买的决策的。那这个季度内呢,这一类的场景,整体辅助实现的保费已经接近1亿元了。那在长险的转化的,尤其是我们服务顾问的服务的场景下,AI的工具主要是能够帮助这些顾问去提升他们的处理信息和展业的效率,然后能够间接地助力转化,然后也能够去释放他们的产能。那这边我们的AI的工具,比如说也有叫核保助手可疑点AI,包括超级售前小助理,这个都在业务中在日常的经营中在落地。那在后台的运营支持的场景方面,我们的AI质检和AI客服等应用也已经是在全量的运营,基本上在全面承接着我们业务规模扩张以及周期内带来的服务量的增长。关于我们在AI上的投入,看问题有问到,就公司的研发费用方面,我们整体的研发费用率确实整体来看还是在比较稳定的一个区间内的。但实际上,从拆开来看,我们还是会在费用的结构上去做一些主动的调优。那主要还是把研发资源向更侧重于AI前沿科技的投入上去做倾斜。那这里面包括我们在算法和模型相关人才梯队的一些建设,那也包括我们在支撑AI应用落地所需要的一些Token相关的成本的投入。那我们预计后续呢,随着AI应用交互量的持续提升,这部分投入肯定还是会预计保持一个自然地增长。那与此同时,我们从财务管理的视角,整体也会去评估在各个场景下这个AI赋能带来的投入产出的效果,把整体的研发费用率还是维持在一个合理的区间内。这是公司整体在AI上的应用的落地,包括价值的衡量,以及我们在研发费用率的投入上的情况。然后还有关于我看也有问题问到我们的创新的业务,其实一直以来我们都还是非常关注是怎么基于我们自身包括在AI应用端我们自己所探索积累下来的一些能力,和我们to C的服务和运营的能力,能够面向更广泛的行业和市场吧,寻找时代创新的机会。那目前我们在做的呢,其实还是依托在,就是在自有业务服务场景下打磨出来的AI Agent的know-how,还有我们自有的研发能力,当然也结合了中国在全额全球的工业体系内的独特的优势。我们也在孵化一款,也在孵化一个定位是随身AI办公助手的智能硬件产品,目前已经在全球主要市场进行了试点的销售,也收到了一些比较初步的积极的反馈。但整体来看,这个业务还是处于比较早期的阶段,还是需要一个周期去验证,包括当前对公司的财务报表影响也是比较有限的。那我们也相信这个过程中积累的经验,无论是对这项业务本身还是对公司整体的能力的沉淀,都是非常有价值的。以上。
Tracy Lee
As previously introduced, our AI is expanding across four value chains: user acquisition, pre-screening, and claims. It rose various by stage.
We're not commercializing AI as a standalone business, and its value will show up in our top-line growth and bottom-line growth we deliver. As our introduced earlier, in the user targeting and conversion, our AI directly support user consultation and purchase decisions, driving nearly 100 million yuan in FYP.
In our long-term insurance advisory tools like our keyi.ai and our AI pre-sales assistant that help our life planners work more efficiently and close more cases. On our operation, our AI customer service and quality inspection applications have fully absorbed actual volume as we scale.
On our R&D side, the overall R&D ratio is stable, but we are actively shifting resources towards AI, both in the talent and in token costs. As usage scales, the spend will grow naturally, but we are disciplined about ROI under each scenario, and it will keep the overall ratio to a reasonable range.
Turning to our new initiatives, we're incubating a portable AI office assistant, a smart hardware product that leverage our AI agent know-how, in-house R&D, and China supply chain strength. It's in pilot sales across major global markets with some encouraging early feedback.
That said, it's still at an early stage and its financial impact is limited for now. The experience we are gaining along the way, both for the business and for the company overall, is generally valuable.
We will now take our next question from Kate Liu of UOB Kay Hian. Her question is, for products and supply perspective, which insurance category does the management feel as having strongest growth potential?
下一个问题来自于大华继显分析师Kate Liu。她的问题是:目前从供给和产品的角度而言,请问管理层认为哪些险种相对更具有发展潜力?
Ran Wei
感谢Kate的提问,这个问题由我来回答。随着居民健康意识的提升,人口老龄化的加剧,健康险正在从标准化产品走向更细分、更贴近实际需求的方向发展。比如说带病体人群适合的健康险,中高端医疗险,以及涵盖健康管理、养老服务等权益属性的产品。以上这些其实是,对我们也是市场看好且判断一致方向的产品。过去传统产品覆盖不到或者服务不够清晰的需求正在被不断地挖掘出来,我们也会持续关注以上几个大方向的机会。还有几类产品,同时的话这几类产品也和我们在线渠道积累的能力是比较契合的。一方面,互联网保险平台规模化的精准获客能力能够打破空间和地域的限制,提高保障的可及性;另一方面,基于长期积累的数据和技术优势,我们能够识别垂类人群的保障缺口,更好地为用户匹配合适的产品,也能针对这类产品普遍存在的咨询需求提供响应更快、也更好的服务。我们会结合自身的平台特点,在这些方向做相应的布局。好。
Tracy Lee
There are two forces reshaping our health insurance: raising health protection awareness and aging population. The market is shifting from the standard life products to more tailor to actual needs.
Demand-driven coverage including our insurance for pre-existing conditions, mid to high-end medical insurance, and products bundled with health management and elderly care services. Demand that traditional product never really served is being unlocked.
We will keep building in this area. This category is playing right into the strength we built through our online platform.
We can reach broadly and target precisely, leveraging our AI capability, and spot protection gaps in specific customer groups, matching them with the right products and deliver better, faster service at a point as the user consultation. We will keep building on what we are uniquely good at.
We will now take our next question from Xinyu Wo of China Securities. The question is, noticing the strong growth in Q2, could you walk us through your recent customer acquisition investment and outcomes, and what we can expect on the cost side for the rest of 2026 and into 2027?
我们的下一个问题来自于中信建投分析师沃心宇。她的问题是:关注到公司在二季度取得的良好增速,那关于获客端的投入以及近期的成果,及2026年下半年和以及至这个2027年的成本展望,是否可以让管理层详细说明一下? 好的,感谢心宇总的提问,这个问题我来回答一下。公司确实在这个季度依然,就是二季度依然是处于一个获客投入的周期里,所以也可以看到我们的保险的业务的收入和营业利润都在26年一季度的基础上有进一步的环比的增长。那这个季度内呢,实际上我们的新用户数环比也增长了30%以上。这个整体看起来也是我们在用户触达、然后这个交互转化和产品供给多方面的综合的持续迭代的一个最终的呈现的结果。那从获客策略上,我们不会去单纯地追求这个成本的单边的下降,更多还是在看在AI能力的加持下,是不是能够更好地去匹配产品供给和用户画像特征,来提升我们的这个转化能力。那前面也介绍了比较多,就是AI如何嵌入到我们从获客到服务的全流程中,怎么在各个核心场景中去助力。那具体的2026年的下半年和2027年的这个全年的周期呢,我们在这个战略的方向上还是保持连续的,所以我们还是会预期一个比较保持积极的获客节奏,提升我们对于目标人群的覆盖,让更多的用户去了解这个保险以及保险配置的价值。同时我们也预期在当前这一个获客投入的周期内带来的这个用户呢,会在后续的整个的用户的生命周期内,通过我们想说当前保单的这个续保,包括说不同险种的复购,或者是这种为家庭去配置的这样的加保的这个用户的购买决策中,把这个用户生命周期的价值逐步地得以释放。这个是我们看当前的获客节奏包括后续的获客的投入,和我们对于更中期用户增长带来的用户价值的综合的一个观点。
Peng Shen
Pursued
Tracy Lee
in an investment circle in user acquisition in Q2, and that speed is already show up in the numbers, like insurance revenue and operating profit, both grew further from last quarter. New users were actually up more than 30% sequentially.
This is a combined results of better outreach and conversion and product supply. In terms of user acquisition strategy, we are not simply pursuing the cost reduction.
What matters most is how we leverage AI capability to better align our product supply with our user profile and improving conversion efficiency. Currently, AI has been embedding across the entire process, from our customer acquisition to service, and is continually improving our efficiency across our core scenarios.
For the second half of 2026 and the full year of 2027, our strategy direction remains consistent. We continue to expect to maintain an active user acquisition pace, extending outreach to target customer segments, and broadening user education coverage.
At the same time, we expect the user value generated by the current period acquisition to be gradually realized through renewals and upsells and cross-sells over the sequential user life circle. We have received no further question online, and this concludes our Q&A session for today.
Thank you to all the investors and analysts who joined us today. Back to operator, back to you.
Operator
We are now approaching the end of the conference call. Thank you for your participation in today's conference.
You may now disconnect. Have a good day.
Already premium?